NO970349L - Forbindelser som er anvendbare som antiproliferative midler og GARFT inhibitorer - Google Patents

Forbindelser som er anvendbare som antiproliferative midler og GARFT inhibitorer

Info

Publication number
NO970349L
NO970349L NO970349A NO970349A NO970349L NO 970349 L NO970349 L NO 970349L NO 970349 A NO970349 A NO 970349A NO 970349 A NO970349 A NO 970349A NO 970349 L NO970349 L NO 970349L
Authority
NO
Norway
Prior art keywords
compounds
antiproliferative agents
compounds useful
garft inhibitors
garft
Prior art date
Application number
NO970349A
Other languages
English (en)
Other versions
NO970349D0 (no
NO308248B1 (no
Inventor
Michael D Varney
Iii William H Romines
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of NO970349D0 publication Critical patent/NO970349D0/no
Publication of NO970349L publication Critical patent/NO970349L/no
Publication of NO308248B1 publication Critical patent/NO308248B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO970349A 1994-07-28 1997-01-27 Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat NO308248B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/281,639 US5608082A (en) 1994-07-28 1994-07-28 Compounds useful as antiproliferative agents and GARFT inhibitors
PCT/US1995/009519 WO1996003406A1 (en) 1994-07-28 1995-07-28 Compounds useful as antiproliferative agents and garft inhibitors

Publications (3)

Publication Number Publication Date
NO970349D0 NO970349D0 (no) 1997-01-27
NO970349L true NO970349L (no) 1997-03-12
NO308248B1 NO308248B1 (no) 2000-08-21

Family

ID=23078167

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970349A NO308248B1 (no) 1994-07-28 1997-01-27 Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat

Country Status (20)

Country Link
US (2) US5608082A (no)
EP (1) EP0773943B1 (no)
JP (1) JPH10503762A (no)
KR (1) KR100380610B1 (no)
CN (2) CN1091770C (no)
AT (1) ATE206122T1 (no)
AU (1) AU697138B2 (no)
CA (1) CA2195420A1 (no)
DE (1) DE69522945T2 (no)
DK (1) DK0773943T3 (no)
ES (1) ES2162933T3 (no)
FI (1) FI112079B (no)
MX (1) MX9700675A (no)
NO (1) NO308248B1 (no)
NZ (1) NZ290703A (no)
PT (1) PT773943E (no)
RU (1) RU2152945C2 (no)
SI (1) SI0773943T1 (no)
TW (1) TW432062B (no)
WO (1) WO1996003406A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831100A (en) * 1995-06-07 1998-11-03 Agouron Pharmaceuticals, Inc. Syntheses of optically pure compounds useful as GARFT inhibitors and their intermediates
WO2001016121A1 (en) * 1999-08-31 2001-03-08 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
AU2002306413A1 (en) * 2001-02-16 2002-10-15 Eli Lilly And Company Use of pyrido`2,3-d pyrimidin derivatives for the treatment of human cytomegalovirus infections
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
MXPA04002537A (es) 2001-10-12 2004-05-31 Warner Lambert Co Alquinos como inhibidores de metaloproteinasa de matriz.
WO2003033478A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
WO2003033477A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor
US20040043959A1 (en) * 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
AU2003249505A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
WO2004113337A1 (en) * 2003-06-25 2004-12-29 Pfizer Inc. Convergent synthesis of a garft inhibitor containing a methyl substitute thiophene core and a tetrahydropyrido`2,3-d! pyrimidine ring system and intermediates therefor
WO2004113328A1 (en) * 2003-06-25 2004-12-29 Pfizer Inc. Convergent asymmetric synthesis route to produce a key intermediate towards the synthesis of a garft inhibitor
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
MX2007013304A (es) 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
MY164457A (en) 2005-09-07 2017-12-15 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase-1
RS20080525A (en) 2006-05-09 2009-09-08 Pfizer Products Inc., Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
US8252804B2 (en) * 2008-10-01 2012-08-28 Duquesne University Of The Holy Spirit Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same
ES2594409T3 (es) 2011-02-23 2016-12-20 Lupin Limited Derivados de heteroarilo como moduladores del nAChR á7
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
WO2013005153A1 (en) 2011-07-05 2013-01-10 Lupin Limited Biaryl derivatives as nachr modulators
US20140309275A1 (en) * 2011-09-29 2014-10-16 Emory University Sphingosine Analogs, Compositions, and Methods Related Thereto
IN2014MN01756A (no) 2012-03-06 2015-07-03 Lupin Ltd
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
CN115634228B (zh) * 2021-07-20 2024-03-19 首都医科大学 嘌呤合成抑制剂在制备治疗缺血和缺血再灌注损伤药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT376436B (de) * 1982-11-05 1984-11-26 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thiophen-2carbons[urederivate und pharmazeutisch vertraeglicher saeure- oder basenadditionssalze davon
US4927828A (en) * 1985-03-08 1990-05-22 The Trustees Of Princeton University Diastereoisomeric tetrahydropyrido-(2,3,d) pyrimidine derivatives
US4684653A (en) * 1985-03-08 1987-08-04 The Trustees Of Princeton University Pyrido(2,3-d)pyrimidine derivatives
US5026851A (en) * 1985-03-08 1991-06-25 The Trustees Of Princeton University Pyrido[2,3-]pyrimidine derivatives
US4831037A (en) * 1987-04-20 1989-05-16 The Trustees Of Princeton University 4 (3H)-oxo-5,6,7,8-tetrahydropyrido-(2,3-d)pyrimidine derivatives
US4988813A (en) * 1986-10-20 1991-01-29 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
US4895946A (en) * 1987-10-26 1990-01-23 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
US4889859A (en) * 1988-02-05 1989-12-26 The Trustees Of Princeton University Pyrido[2,3-d]pyrimidine derivatives
US4882333A (en) * 1988-05-25 1989-11-21 The Trustess Of Princeton University N-(5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl-alkanoyl)-glutamic acid derivatives
US4882334A (en) * 1988-05-25 1989-11-21 The Trustees Of Princeton University N-(5,6,7,8-tetrahydropyrido]2,3-d]pyrimidin-6-ylethl-thineyl-and furylcarbonyl)-glutamic acid derivatives
DK172753B1 (da) * 1988-05-25 1999-06-28 Lilly Co Eli N-(5,6,7,8-tetrahydropyrido[2,3--d]pyrimidin-6-yl-alkanoyl)-glutaminsyrederivater, deres anvendelse, farmaceutiske præparat
US4871746A (en) * 1988-05-31 1989-10-03 The Trustees Of Princeton University N-[N-(tetrahydropyrido[2,3-D]pyrimidinylmethyl)-aminomethylbenzoyl]glutamic acid derivatives as neoplastic growth inhibitors
US4883799A (en) * 1988-06-29 1989-11-28 The Trustees Of Princeton University N-(4-(1-hydroxy-3-(5,6,7,8-tetrahydropyrido(2,3,-d)-pyrimidin-6-yl)prop-2-yl)benzoyl)glutamic acid derivatives
EP0438261A3 (en) * 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
IL99500A0 (en) * 1990-09-17 1992-08-18 Agouron Pharma Naphthalene compounds,processes for the preparation thereof and pharmaceutical compositions containing the same
US5217974A (en) * 1991-03-29 1993-06-08 Eli Lilly And Company Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity
US5223503A (en) * 1991-04-29 1993-06-29 Eli Lilly And Company 6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents
US5969136A (en) * 1992-10-15 1999-10-19 Eli Lilly And Company Cyclization for preparing antifolate compounds
CA2151588C (en) * 1992-12-16 2002-03-19 Michael D. Varney Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone

Also Published As

Publication number Publication date
EP0773943A1 (en) 1997-05-21
AU697138B2 (en) 1998-09-24
US5646141A (en) 1997-07-08
AU3151795A (en) 1996-02-22
TW432062B (en) 2001-05-01
US5608082A (en) 1997-03-04
NO970349D0 (no) 1997-01-27
DE69522945T2 (de) 2002-03-28
CA2195420A1 (en) 1996-02-08
DK0773943T3 (da) 2002-03-04
EP0773943B1 (en) 2001-09-26
DE69522945D1 (de) 2001-10-31
ATE206122T1 (de) 2001-10-15
ES2162933T3 (es) 2002-01-16
NZ290703A (en) 1998-11-25
FI970317A (fi) 1997-03-05
CN1394857A (zh) 2003-02-05
FI970317A0 (fi) 1997-01-24
CN1154110A (zh) 1997-07-09
PT773943E (pt) 2002-01-30
NO308248B1 (no) 2000-08-21
SI0773943T1 (en) 2001-12-31
CN1091770C (zh) 2002-10-02
KR100380610B1 (ko) 2003-08-27
RU2152945C2 (ru) 2000-07-20
MX9700675A (es) 1997-04-30
WO1996003406A1 (en) 1996-02-08
FI112079B (fi) 2003-10-31
JPH10503762A (ja) 1998-04-07

Similar Documents

Publication Publication Date Title
NO970349D0 (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT inhibitorer
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
SE0302487D0 (sv) Novel compounds
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
ATE297203T1 (de) Antithrombotische mitteln
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
NO20085077L (no) Nye forbindelser
DE602004012758D1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
MY143400A (en) 2-pyridone derivatives as neutrophil elastase inhibitors and their use
NZ514477A (en) Adamantane derivatives
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
IL151172A0 (en) Amine derivatives, their preparation and use as bax modulators
SE0302323D0 (sv) Novel compounds
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
NO20040881L (no) Orale antidiabetes midler.
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
NO20000722L (no) 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater
PT992509E (pt) Novos derivados macrolidos
ATE505462T1 (de) Neue biologischaktive molekü le
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
DK0902018T3 (da) 2-(arylpheny)amino-imidazolinderivater

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees